Long Term Aml Survivors Have Increased Mortality And High Prevalence Of Clonal Hematopoiesis

Acute myeloid leukemia (AML) is a devastating disease; however 20%-30% of patients will achieve long term remission. The long-term follow up of AML patients who received bone marrow transplantation (BMT) is well documented. It remains unclear though whether AML long-term survivors who did not undergo BMT (LTSnoBMT) return to normal health. In order to answer this question a large cohort of AML patients and well matched controls are needed. For the present study, the electronic health records (EHR) of 4.2 million individuals covering over 16 years of follow up were studied. Morbidity and mortality of LTSnoBMT were compared to a large number of age-matched controls.